Market Outlook - Victoria Greene emphasizes the importance of focusing on company fundamentals as financial earnings season begins, expecting higher volatility in the market this year [1] - Julian Emanuel maintains a bullish target of 7,750 for the S&P 500, citing continued leadership in communication services, consumer discretionary, and IT driven by AI [2] - Emanuel expresses optimism about the upcoming earnings season, noting consistently high "beat rates" and potential risks related to Fed policies [3] Company Highlights - Jade Biosciences Inc. (NASDAQ:JBIO) is positioned to lead in the autoimmune market, with a projected revenue of $926 million from its treatment candidate JADE101 by 2037 [9] - Biomea Fusion Inc. (NASDAQ:BMEA) is focusing on its primary assets icovamenib and BMF-650, with promising Phase II study results showing a sustained 1.5% reduction in HbA1c for diabetes patients [13][15]